US 11,992,659 B2
Controllable drug delivery system and method of use
Adam B. McCullough, Westlake Village, CA (US); Ferry Tamtoro, San Ramon, CA (US); Huaying Yang, Vernon Hills, IL (US); Mark Ka Lai Lee, Newbury Park, CA (US); Desheng Yin, Thousand Oaks, CA (US); Scott R. Gibson, Simi Valley, CA (US); Donald Busby, Thousand Oaks, CA (US); Peter V. Shultz, Woodland Hills, CA (US); Keith P. Kogler, Simi Valley, CA (US); Basel Hasan Taha, Westlake Village, CA (US); Jimmie L. Ward, Camarillo, CA (US); Christopher R. Folk, San Diego, CA (US); and Steven William Badelt, Los Angeles, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Nov. 23, 2021, as Appl. No. 17/534,173.
Application 17/534,173 is a continuation of application No. 16/843,622, filed on Apr. 8, 2020, granted, now 11,213,624.
Application 16/843,622 is a continuation of application No. 15/315,829, granted, now 10,646,652, previously published as PCT/US2015/033933, filed on Jun. 3, 2015.
Claims priority of provisional application 62/007,007, filed on Jun. 3, 2014.
Prior Publication US 2022/0257862 A1, Aug. 18, 2022
Int. Cl. A61M 5/142 (2006.01); A61M 5/158 (2006.01); A61M 5/20 (2006.01); A61M 5/24 (2006.01); A61M 5/315 (2006.01); A61M 5/32 (2006.01); A61M 5/50 (2006.01); G06Q 50/00 (2012.01); G06Q 50/22 (2018.01); G16H 20/17 (2018.01); G16H 40/00 (2018.01); G16H 40/63 (2018.01); G16H 40/67 (2018.01)
CPC A61M 5/20 (2013.01) [A61M 5/14244 (2013.01); A61M 5/14248 (2013.01); A61M 5/158 (2013.01); A61M 5/24 (2013.01); A61M 5/31501 (2013.01); A61M 5/31568 (2013.01); A61M 5/3202 (2013.01); A61M 5/3243 (2013.01); A61M 5/3257 (2013.01); A61M 5/326 (2013.01); A61M 5/5086 (2013.01); G06Q 50/01 (2013.01); G06Q 50/22 (2013.01); G16H 20/17 (2018.01); G16H 40/00 (2018.01); G16H 40/63 (2018.01); G16H 40/67 (2018.01); A61M 2005/3267 (2013.01); A61M 2205/3331 (2013.01); A61M 2205/3368 (2013.01); A61M 2205/3553 (2013.01); A61M 2205/3576 (2013.01); A61M 2205/50 (2013.01); A61M 2205/502 (2013.01); A61M 2205/52 (2013.01); A61M 2205/581 (2013.01); A61M 2205/6009 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A drug delivery device comprising:
a reservoir;
a delivery member having a proximal end connected or configured to be connected in fluid communication with the reservoir and a distal end configured for insertion into a patient;
a housing having an opening, the distal end of the delivery member being configured to extend through the opening in an operative state;
an adhesive for removably coupling the housing to skin of the patient;
a removable cover covering at least a portion of the adhesive;
a controllable element;
a patient contact sensor; and
the drug delivery device being programmed or configured to:
(a) determine if the at least a portion of the adhesive has been exposed,
(b) determine if the drug delivery device is in contact with the patient, and
(c) subsequent to or simultaneously with (b), output a control signal to the controllable element.